ea0038p58 | Clinical practice/governance and case reports | SFEBES2015
, Fletcher Simon
, Dunn Janet
, Hewison Martin
, Bland Rosemary
End stage renal disease (ESRD) is characterised by decreased renal synthesis of 1,25-dihydroxyvitamin D (1,25D). Therapeutic use of 1,25D analogues for the management of renal bone disease is routine. However ESRD patients are also deficient in 25D (the immediate precursor of 1,25D). Since 2014 UK guidelines recommend diagnosis and treatment of 25D deficiency/insufficiency in people with chronic kidney disease, but make no recommendations for dosage or monitoring. This, togeth...